相关实验视频
Updated: Jul 3, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
托法西提尼布在性结肠炎中的使用:对日常临床实践的专家共识
Rupa Banerjee1, Vishal Sharma2, Rajendra Patel3
1Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Mindspace Road, Gachibowli, Hyderabad, 500 032, India. dr_rupa_banerjee@hotmail.com.
托法西提尼布为性结肠炎提供了一种有价值的治疗选择,有助于诱导和维持缓解,特别是在其他疗法失败后. 由于感染和血栓形成等潜在风险,仔细选择和监测患者至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 全球炎症性肠病 (IBD) 发病率的增加.
- 需要关于性结肠炎 (UC) 先进疗法的临床指导.
- 托法西提尼布作为用于UC治疗的Janus激酶 (JAK) 抑制剂.
研究的目的:
- 为了提供专家对托法西提尼布在性结肠炎中使用的共识.
- 为临床医生提供有关适当剂量,患者选择和风险管理的指导.
- 概述托法西提尼布在诱导和维持UC缓解中的作用.
主要方法:
- 创建一个专家共识文件.
- 对tofacitinib在性结肠炎中的临床证据的审查.
- 为临床实践制定建议.
主要成果:
- 托法西替尼在UC中诱导和维持缓解是有效的.
- 推的诱导剂量:10毫克每天两次 (BD);维持剂量:响应后5毫克BD.
- 禁忌/预防措施包括老年人,心血管风险,血栓形成史,恶性瘤风险和特定感染.
结论:
- 托法西提尼布是一种可行的选择,用于生物耐火性,类固醇依赖性或硫氨酸耐火性UC.
- 治疗前对感染 (乙型肝炎,结核病) 和接种疫苗 (疹) 的查至关重要.
- 由于感染和血栓形成风险增加,在特定患者群体中使用需要谨慎.
更多相关视频
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...